• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Cytovance Biologics

    Alcami

    Syngene

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Federal Equipment Company

    Emergent BioSolutions

    Aphena Pharma Solutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Ensuring Manufacturing Continuity for Essential Medicines

    Applying the principles of Quality Risk Management to get medicines to market faster.

    Ensuring Manufacturing Continuity for Essential Medicines
    John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc.09.09.20
    As vaccine development progresses globally to address the coronavirus pandemic, assurance of manufacturing capability to address supply needs is critical to successful treatment and eradication of the virus. At the time of writing, the World Health Organization (WHO), in its database of Covid-19 candidate vaccines, is tracking the development of 163 candidates in various stages of pre-clinical or clinical development to treat Covid-19.1 Allied to this, government and regulatory agencies around the world are implementing measures to ensure that successful candidate vaccines can be approved rapidly and progressed to large scale manufacture in an accelerated fashion in order to ensure that successful vaccines which are safe and effective are made available globally.

    In order to facilitate a seamless transition from clinical to full-scale manufacture and to ensure continuity of supply, it may be possible to introduce some flexibilities into manufacturing processes provided there is sufficient attention given to the risks associated with applying these flexibilities. Manufacturers wishing to provide support to development companies will have a responsibility to manage the risk associated with rapid pivot into new processes to manufacture previously unmanufactured products as quickly as possible without compromising user safety.

    Regulatory overview
    As far back as 2011, FDA gave consideration to ensuring supply of necessary medicines. The FDA guidance document titled, “Planning For The Effects Of High Absenteeism To Ensure Availability Of Medically Necessary Drug Products,”2 outlines measures such as production equipment routine maintenance and utility system performance checks and maintenance which may be reduced in frequency, delayed, or substituted by a suitable alternative when there is a requirement for continued supply of medically necessary products.

    As part of Operation Warp Speed, the U.S. government has committed to ensuring continuity of supply as scale up manufacture of critical vaccines occur by funding investment in manufacturing facilities and by indicating that accelerated manufacture can be facilitated while products are still in development, rather than being subject to scale-up after approval or authorization, as is traditionally the case.3

    In Europe, the European Medicines Agency (EMA) has published a Notice to Stakeholders entitled, “Question and Answers on Regulatory Expectations for Medicinal Products for Human Use During the Covid-19 Pandemic.”4 

    Consideration has been given to both temporary changes that can be built into existing quality systems, such as periodic review of quality documents; periodic re-trainings and deferral of stability testing of non-essential medicines, as well as bandwidth enhancements where there is a requirement for re-purposing of facilities and personnel in order to meet demand and ensure continuous availability such as the introduction of premises and equipment following limited prospective qualification and the performance of concurrent validation of a new manufacturing process. In all instances, specific criteria are laid out in order to ensure that the necessary guard rails are in place to prevent any impact on product quality, safety and efficacy arising out of the introduced changes.

    Where there is a requirement to introduce premises and equipment following limited qualification, a number of factors are required to be considered such as application of Quality Risk Management to ensure that the appropriate level of qualification is carried out before proceeding, additional mitigation measures are introduced to verify the process and a commitment to resume regular qualification tasks at a time when there is no longer a need for flexibility to ensure rapid delivery of products.

    Where concurrent validation approaches are considered, data-based evidence is required to show that acceptance criteria are being met. Additionally, equipment and test methods must be qualified and validated before proceeding with a concurrent validation strategy. Where the product is a sterile product, sterility assurance processes are required to be validated prior to commencing concurrent process validation.4

    Both FDA and EU have documented guidance on concurrent validation. The FDA guidance, “Process Validation: General Principles and Practices,”5 provides clear recommendations to manufacturers regarding concurrent validation strategies, focusing on robust systems for oversight of distributed product, rapid assessment of complaints and inclusion of batches in the stability program undertaken. Additionally, FDA recommends that stability data associated with the batches manufactured via the concurrent validation strategy are immediately reviewed to ensure that any problems are identified as early as possible.

    Challenges for manufacturers
    The key driver in allowing the introduction of GMP flexibilities into manufacturing processes and associated GMP activities is to ensure rapid delivery of essential medicine. However, these flexibilities do not absolve manufacturers of their regulatory and product quality responsibilities and it is crucial that Quality Risk Management principles are employed in order to assess manufacturing capability of the candidate product, underpinned by robust, mature quality systems to defend against non-conformance.

    Manufacturers seeking approval to provide extra capability will be obliged to prove that existing quality systems can cope with new product and process introduction, however temporary, and display a history of compliance with other products manufactured at the proposed site. Close collaboration with the development site is critical to ensure that the requirements for manufacture of the new product can be met by the proposed manufacturing site and that current systems, capabilities and controls in place are suitable to ensure that product quality can be guaranteed when the new product is introduced.

    One approach which can address these needs is the completion of risk assessments in key areas in order to ascertain the suitability of the site to manufacture with the appropriate flexibilities employed to ensure rapid delivery of medicine.

    Key focus areas for risk assessment include:

    •  Facility Assessment
    Assurance that the facilities and utilities in place can meet the manufacturing requirements of the product from both process and capacity perspectives.

    • Technical Assessment
    Sufficient understanding of the proposed product-specific manufacturing process and analytical methodologies to assure that full scale manufacture and testing can be implemented without delay.

    • Operational Assessment
    Assessment of current operational procedures, controls, and resources to ensure compatibility and capability.

    • Contamination Assessment
    Determination of the contamination risk associated with the introduction of the new product into the facility and equipment.

    • Cleaning Assessment (Chemical and Microbiological)
    Review of currently employed methodologies to confirm compatibility with the new product into the facility and equipment along with analytical capabilities to test samples.

    • Quality Assessment
    Assure the robustness of current quality system to determine that the facility will continue to operate in an overall state of control upon introduction of the new product. Strong, mature quality systems such as change control, deviation management and complaints management are key risk mitigating factors when considering the introduction of a new product and a significant guard rail where steps are being taken to accelerate manufacture of essential medicines.

    Successful completion of assessments such as these provide, in their totality, an overall picture of the compliance landscape of the proposed manufacturing site to the regulator and, in turn, a level of confidence that appropriate measures are in place to mitigate the risk associated with the introduction of a new product in a short period of time, abridged technical transfer protocols and the implementation of flexibilities in traditional activities such as process validation in order to ensure supply of medicine as quickly as possible.

    Conclusion
    The coronavirus pandemic has placed huge focus on the pharmaceutical industry in its entirety, from product development, through clinical trials, to manufacture and distribution of a safe and effective vaccine. Regulatory bodies and the industry have come together for the common good to implement structures to make a vaccine available as soon as is feasible. This involves some flexibility in order to accelerate the many processes which bring a product to the patient and it is incumbent on manufacturers to ensure that the introduction of these flexibilities does not impact product quality, safety and efficacy and thereby put vaccine recipients at risk. Application of Quality Risk Management tools is crucial to ensuring that manufactured product consistently meets these criteria and that products which are ultimately made available make it possible for healthcare systems around the world to treat Covid-19 and minimize its devastating effects. 

    References
    1. World Health Organization, “Draft landscape of COVID-19 candidate vaccines”, August 20, 2020, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
    2. U.S. Food and Drug Administration, “Guidance for Industry - Planning For The Effects Of High Absenteeism To Ensure Availability Of Medically Necessary Drug Products”, March 2011, https://www.fda.gov/media/120092/download.
    3. U.S. Department of Health and Human Services, “Trump Administration Announces Framework and Leadership for ‘Operation Warp Speed’”, May 15, 2020 https://www.hhs.gov/about/news/2020/05/15/trump-administration-announces-framework-and-leadership-for-operation-warp-speed.html.
    4. European Commission, Heads of Medicines Agency, and European Medicines Agency, “Notice to Stakeholders - Questions and Answers on Regulatory Expectations for Medicinal Products for Human Use During the Covid-19 Pandemic”, Rev. 3 July 1, 2020, https://ec.europa.eu/health/sites/health/files/human-use/docs/guidance_regulatory_covid19_en.pdf.
    5. U.S. Food and Drug Administration, “Guidance for Industry - Process Validation: General Principles and Practices”, January 2011, https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf.


    John Darby, M.Sc., Senior Director
    Lachman Consultant Services, Inc.


    John Darby, M.Sc. is a Senior Director in the Compliance Practice at Lachman Consultants. Mr. Darby is a goal directed, results-focused executive professional with a strong, global background in quality assurance, compliance, audits, training, and remediation. With over 18 years of experience, Mr. Darby has been responsible for the management, organization, and strategic guidance of global, quality and operations-based training functions. He is proficient in sterile pharmaceutical manufacture, oral solid dose manufacture and API manufacture.
    Related Searches
    • Biologics, Proteins, Vaccines

    Related FDA Watch

    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20

    • Biologics, Proteins, Vaccines | Biosimilars | Chemistry | GMPs/GCPs | Inspections | Laboratory Testing | Regulatory Affairs

      Biosimilar Milestone

      FDA provides draft guidance on biosimilar product development
      Heather Banuelos 04.04.12

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login